Janssen Oncology Strategy: Take A Holistic Approach To R&D
Executive Summary
With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.
You may also be interested in...
J&J Growth Plans Heavy On Line Extensions, Sticking With Immunology And Oncology
Recent launches Tremfya and Erleada are viewed as catalysts for continuing growth, along with ambitious plans to add indications for Imbruvica, Darzalex and Stelara.
Another Sea Change In Myeloma Promised By New Therapies, Combos
Darzalex made a splash with impressive Phase III data in relapsed multiple myeloma at the EHA and ASCO meetings, but a range of other drugs are on the way, including a next-generation CD38 inhibitor from Sanofi, checkpoint inhibitors and Roche's BCL-2 Venclexta.
CASTOR Propels J&J's Anti-CD38 Darzalex To Prime Position In Myeloma
Lead investigator says anti-38 antibody daratumumab compares well in earlier-stage relapsed disease to other myeloma drugs and advises using it early on the basis of "unprecedented" benefit.